Clinical Trial Update: Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Benserazide (100/25 mg) [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic-pharmacodynamic interaction study assessing four single doses of BIA 3-202 with a single dose of Levodopa/Benserazide (100/25 mg) in Par…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• BIA 3-202
• Levodopa/Benserazide (levodopa + benserazide)

Snippet

Sponsor: Bial - Portela C S.A. | Conditions: Parkinson's Disease | Phase 1 | Status: COMPLETED